Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis
- 20 March 2024
- journal article
- review article
- Published by Elsevier in Endocrine Practice
- Vol. 30 (5) , 431-440
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Baricitinib and β-Cell Function in Patients with New-Onset Type 1 DiabetesNew England Journal of Medicine, 2023
- Teplizumab and β-Cell Function in Newly Diagnosed Type 1 DiabetesNew England Journal of Medicine, 2023
- A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumabDiabetologia, 2023
- Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosisDiabetologia, 2018
- Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trialDiabetologia, 2012
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trialThe Lancet, 2011
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011
- Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 yearsClinical Immunology, 2009
- Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes MellitusNew England Journal of Medicine, 2002
- A Randomized Trial of Methotrexate in Newly Diagnosed Patients with Type 1 Diabetes MellitusClinical Immunology, 2000